Sino Biopharmaceutical (HKG:1177) presented the latest results of the phase III clinical study for benmelstobart injection in combination with anlotinib hydrochloride capsules at the American Society of Clinical Oncology's annual meeting

The drug is being tested as first-line treatment for non-small cell lung cancer in comparison with the pembrolizumab injection.

The study has achieved the primary study endpoint of progression-free survival, in which the median survival was prolonged by more than 6 months in the population with TPS ≥50%.

There was also a 40% reduction in the risk of disease progression and death as compared with the arm of pembrolizumab.